- Home
- BCDA vs SIDU Comparison
BCDA vs SIDU Comparison
Compare BCDA & SIDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- SIDU
- Stock Information
- Founded
- BCDA N/A
- SIDU 2012
- Country
- BCDA United States
- SIDU United States
- Employees
- BCDA N/A
- SIDU N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- SIDU Telecommunications Equipment
- Sector
- BCDA Health Care
- SIDU Telecommunications
- Exchange
- BCDA Nasdaq
- SIDU Nasdaq
- Market Cap
- BCDA 7.9M
- SIDU 10.3M
- IPO Year
- BCDA N/A
- SIDU 2021
- Fundamental
- Price
- BCDA $2.68
- SIDU $2.51
- Analyst Decision
- BCDA Strong Buy
- SIDU Strong Buy
- Analyst Count
- BCDA 1
- SIDU 1
- Target Price
- BCDA $25.00
- SIDU $10.00
- AVG Volume (30 Days)
- BCDA 73.1K
- SIDU 361.5K
- Earning Date
- BCDA 11-06-2024
- SIDU 11-12-2024
- Dividend Yield
- BCDA N/A
- SIDU N/A
- EPS Growth
- BCDA N/A
- SIDU N/A
- EPS
- BCDA N/A
- SIDU N/A
- Revenue
- BCDA $428,000.00
- SIDU $4,306,474.00
- Revenue This Year
- BCDA $6.92
- SIDU $36.85
- Revenue Next Year
- BCDA N/A
- SIDU $40.00
- P/E Ratio
- BCDA N/A
- SIDU N/A
- Revenue Growth
- BCDA 0.71
- SIDU N/A
- 52 Week Low
- BCDA $1.96
- SIDU $2.02
- 52 Week High
- BCDA $23.25
- SIDU $18.85
- Technical
- Relative Strength Index (RSI)
- BCDA 49.01
- SIDU 45.84
- Support Level
- BCDA $2.39
- SIDU $2.14
- Resistance Level
- BCDA $2.90
- SIDU $2.94
- Average True Range (ATR)
- BCDA 0.18
- SIDU 0.21
- MACD
- BCDA -0.00
- SIDU -0.02
- Stochastic Oscillator
- BCDA 53.70
- SIDU 47.30
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About SIDU Sidus Space Inc.
Sidus Space Inc is a Space and Defense as-a-Service company focused on providing complex space hardware, satellite/spacecraft design, manufacture, launch, and data solutions for both government and commercial in-space missions for all destinations through the solar system. This includes a Space-based infrastructure of multi-mission satellites with hyperspectral, multi-spectral, and other sensors to provide monitoring services and solutions to multiple sectors and industries. The company supports Commercial Space, Aerospace, Defense, Underwater Marine, and other commercial and government customers.